Drug intelligence / Profile preview

mRNA-6981

Development stage: Discontinued
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

mRNA-6981 is a **preclinical mRNA therapeutic** from **Moderna** designed for autoimmune disease, initially prioritized for **type 1 autoimmune hepatitis**. It encodes **programmed death-ligand 1**, with the intent of increasing **cell-surface PD-L1 expression on myeloid cells** and thereby delivering co-inhibitory signals to self-reactive lymphocytes to dampen pathological autoimmunity. The candidate was described as using the same lipid nanoparticle formulation as mRNA-1944, but Moderna later **discontinued** development of the PD-L1 program before clinical advancement.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on mRNA-6981.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mRNA-6981.

Explore the full profile